Exploring protein indicators in mild cognitive impairment and Alzheimer's disease
Exploring Research on Early Warning Indicators of Protein in Patients With Mild Cognitive Impairment and Alzheimer's Disease
Guangzhou University of Traditional Chinese Medicine · NCT04804618
This study is trying to find early signs in blood and other samples from people with mild cognitive impairment or Alzheimer's disease that could help diagnose and prevent Alzheimer's.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 650 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | Guangzhou University of Traditional Chinese Medicine (other) |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04804618 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect biological specimens such as blood, feces, urine, saliva, and tongue coating from individuals diagnosed with mild cognitive impairment or Alzheimer's disease. Utilizing advanced liquid chromatography/mass spectrometry (LC-MS/MS) technology, the study seeks to identify early warning indicators of protein that could aid in the diagnosis and prevention of Alzheimer's disease. The research is motivated by the increasing prevalence of dementia and the need for non-invasive diagnostic methods. By focusing on proteomics, the study hopes to contribute to the understanding of disease markers and potential therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals over 55 years old diagnosed with mild cognitive impairment or Alzheimer's disease, or those with a family history of Alzheimer's.
Not a fit: Patients with acute cardiovascular or cerebrovascular diseases, severe infections, or pregnant or lactating women may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of Alzheimer's disease, improving patient outcomes.
How similar studies have performed: While proteomics research is a growing field, this specific approach to early diagnosis in Alzheimer's disease is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Older than 55-year-old，male or female. 2. patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD 3. Complete self-rating scale for memory impairment (AD-8 scale) 4. Those who agree to participate in clinical research and sign informed consent. Exclusion Criteria: 1. Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia; 2. Pregnant or lactating women;
Where this trial is running
Guangzhou, Guangdong
- Guangdong Province Hospital of Tradtional Chinese Medicine — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: jianwen guo, Dr
- Email: 306247680@qq.com
- Phone: 13724899379
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer Disease, Early Onset, Protein, Disease, Alzheimer Disease, biomarker, protein